Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | PTPRC | P08575 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213583 | 0.98 | CES1 (0.72) | CES1ALDH1A1HSD17B10PTPRCMEN1 | |
| SCHEMBL380656 | 0.82 | CES1 (1.00) | CES1ALDH1A1HSD17B10PTPRCMEN1 | |
| SCHEMBL29460197 | 0.78 | CES1 (0.83) | CES1ALDH1A1HSD17B10PTPRCMEN1 | |
| SCHEMBL2995536 | 0.75 | CES1 (0.54) | CES1ALDH1A1HSD17B10PTPRCMEN1 | |
| SCHEMBL22609991 | 0.74 | CES1 (0.81) | CES1ALDH1A1HSD17B10PTPRCMEN1 | |
| Furan SCHEMBL3095660 | 0.74 | CES1 (0.81) | CES1ALDH1A1HSD17B10PTPRCMEN1 | |
| SCHEMBL29447251 | 0.74 | ALDH1A1 (0.64) | CES1ALDH1A1HSD17B10MEN1LMNA | |
| SCHEMBL2957612 | 0.74 | ALDH1A1 (0.64) | CES1ALDH1A1HSD17B10MEN1LMNA | |
| Anthracene SCHEMBL28233789 | 0.72 | CES1 (0.39) | CES1ALDH1A1HSD17B10MEN1HPGD | |
| SCHEMBL146910 | 0.72 | PTPRC (0.53) | CES1ALDH1A1HSD17B10PTPRCMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0940144-A1 | BIOACTIVE POLYMER PRODUCT | EBARA CORPORATION (JP) | 1999-09-08 | — | — | EP | claimed |
| WO-1998011230-A1 | POLYKETIDE SYNTHASES FOR PRADIMICIN BIOSYNTHESIS AND DNA SEQUENCES ENCODING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-03-19 | — | — | WO | claimed |
| EP-3383405-B1 | ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF | FONDAZIONE ST INSUBRICO DI RICERCA PER LA VITA (IT) | 2024-06-12 | — | — | EP | disclosed |
| EP-3601246-B1 | 16-METHYL-OXACYCLOHEXADECAN-2-ONE AND 16-METHYL-AZACYCLOHEXADECAN-2-ONE DERIVATIVES AS ANTIMICROBIAL AGENTS | THE UNIV OF MONTANA (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3601246-A1 | 16-METHYL-OXACYCLOHEXADECAN-2-ONE AND 16-METHYL-AZACYCLOHEXADECAN-2-ONE DERIVATIVES AS ANTIMICROBIAL AGENTS | The University Of Montana (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20190002942-A1 | ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF | FONDAZIONE ISTITUTO INSUBRICO DI RICERCA PER LA VITA (IT) | 2019-01-03 | — | — | US | disclosed |
| EP-3383405-A1 | ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF | Fondazione Istituto Insubrico di Ricerca per la Vita (IT) | 2018-10-10 | — | — | EP | disclosed |
| WO-2018175418-A1 | 16-METHYL-OXACYCLOHEXADECAN-2-ONE AND 16-METHYL-AZACYCLOHEXADECAN-2-ONE DERIVATIVES AS ANTIMICROBIAL AGENTS | THE UNIVERSITY OF MONTANA (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2017093114-A1 | ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF | FONDAZIONE ISTITUTO INSUBRICO DI RICERCA PER LA VITA (IT) | 2017-06-08 | — | — | WO | disclosed |
| EP-2500437-B1 | Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same | PTC THERAPEUTICS INC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9493845-B2 | Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same | PTC THERAPEUTICS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-0937082-A2 | MATERIALS AND METHOD FOR TREATING OR PREVENTING PATHOGENIC FUNGAL INFECTION | ARIAD PHARMACEUTICALS, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998011230-A1 | POLYKETIDE SYNTHASES FOR PRADIMICIN BIOSYNTHESIS AND DNA SEQUENCES ENCODING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998002441-A2 | NON IMMUNOSUPPRESSIVE ANTIFUNGAL RAPALOGS | ARIAD PHARMACEUTICALS, INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| EP-0684253-A1 | DESALANINEBENANOMICIN A DERIVATIVE AND PRODUCTION THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1995-11-29 | — | — | EP | disclosed |
| US-5110960-A | Tetracycline, anthracycline and anthraquinone antibiotics | BRISTOL-MYERS COMPANY (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0277621-B1 | ANTIFUNGAL ANTIBIOTICS | Bristol-Myers Squibb Company (US) | 1992-02-05 | — | — | EP | disclosed |
| US-4990497-A | Antifungal antibiotics | OKI TOSHIKAZU (JP) | 1991-02-05 | — | — | US | disclosed |
| US-4870165-A | TETRACYCLINE-TYPE | BRISTOL-MYERS COMPANY (US) | 1989-09-26 | — | — | US | disclosed |
| EP-0277621-A1 | Antifungal antibiotics | Bristol-Myers Squibb Company (US) | 1988-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002942-A1 | ANTIBIOTIC FIIRV 104/18 COMPLEX AND THE ISOLATED INDIVIDUAL FACTORS THEREOF | MRPL38, F5, F8 | CES1 4354/4885ALDH1A1 4070/4885HSD17B10 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.